Lupus erythematosus - Lupus Eritematós
☆ En els resultats de la Stiftung Warentest d'Alemanya de 2022, la satisfacció dels consumidors amb ModelDerm va ser només lleugerament inferior a la de les consultes de telemedicina de pagament.
Apareix com un eritema lleugerament porpra.
L'erupció de papallona que apareix normalment a la cara.
References
Identificar i classificar cutaneous lupus erythematosus (CLE) planteja reptes diagnòstics, distingint-lo de systemic lupus erythematosus amb afectació de la pell. Estudis recents aclareixen els factors genètics, ambientals i immunològics subjacents al CLE. La inducció de drogues s'ha convertit específicament en un dels desencadenants més importants de CLE. El tractament inclou teràpies tòpics i sistèmiques, incloent biològics prometedors com belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 , amb eficàcia demostrada en assaigs clínics.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) cobreix diversos problemes de la pell, alguns dels quals poden relacionar-se amb problemes de salut més amplis. Es classifica en diferents tipus, com ara acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE inclou discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus és un grup de malalties autoimmunes que poden afectar diferents parts del cos. Alguns tipus, com systemic lupus erythematosus (SLE) , afecten diversos òrgans, mentre que altres, com cutaneous lupus erythematosus (CLE) , afecten principalment la pell. Categoritzem diferents tipus de CLE en funció d'una combinació de signes clínics, examen de teixits i anàlisis de sang, però hi ha moltes variacions entre individus. Els problemes de la pell sovint es desenvolupen a causa de factors com l'exposició a la llum solar, el tabaquisme o determinats medicaments.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
La causa del lupus eritematós (lupus erythematosus) no està clara. Entre els bessons idèntics, si un està afectat, hi ha un 24% de possibilitats que l'altre també ho sigui. També es creu que les hormones sexuals femenines, la llum solar, el tabaquisme, la deficiència de vitamina D i certes infeccions augmenten el risc.
Els tractaments poden incloure AINE, corticoides, immunosupressors, hidroxicloroquina i metotrexat. Tot i que els corticoides són efectius, l'ús a llarg termini provoca efectes secundaris.